Rohto Pharmaceutical Co.,Ltd. (TYO:4527)

Rohto Pharmaceutical Financials Overview

Financials in millions JPY. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	353,385	343,725	308,625	270,840	238,664	199,646
Revenue Growth	9.67%	11.37%	13.95%	13.48%	19.54%	10.13%
Gross Profit Gross Profit Growth	198,436	192,695	174,939	157,286	137,421	116,489
Operating Income Operating Income Growth	42,653	40,706	38,465	40,167	33,538	28,192
Net Income Net Income Growth	33,128	34,247	31,006	30,936	26,377	21,018
Earnings Per Share EPS Growth	140.53	145.29	135.44	135.21	115.29	91.86
EPS Growth	-6.16%	7.27%	0.17%	17.28%	25.50%	25.53%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Europe Europe Growth	25,265	24,093	19,334	14,015	12,247	10,344
Unallocated Adjustment Unallocated Adjustment Growth	-11,777	-12,321	-11,442	-9,357	-8,947	-7,565
Japan Japan Growth	175,950	173,997	168,852	160,168	140,510	124,800
Americas Americas Growth	23,615	23,156	22,593	20,074	18,076	11,187
Others Others Growth	3,809	3,689	3,451	2,830	2,381	1,964
Asia Asia Growth	136,519	131,109	105,835	83,108	74,395	58,915
Total Total Growth	353,381	343,723	308,623	270,838	238,662	199,645

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	84,771	86,816	77,161	89,210	79,951	72,791
Total Debt Total Debt Growth	58,101	60,244	50,223	10,494	11,693	21,383
Net Cash (Debt) Net Cash Growth	26,670	26,572	26,938	78,716	68,258	51,408
Net Cash Growth	-1.06%	-1.36%	-65.78%	15.32%	32.78%	14.58%
Net Cash Per Share Net Cash Per Share Growth	113.26	112.85	117.69	344.04	298.33	224.69

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	47,788	36,917	34,245	30,924	27,250
Capital Expenditures CapEx Growth	-	-11,494	-9,080	-7,979	-8,473	-10,267
Free Cash Flow Free Cash Flow Growth	-	36,294	27,837	26,266	22,451	16,983
Free Cash Flow Growth	-	30.38%	5.98%	16.99%	32.20%	50.47%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	56.15%	56.06%	56.68%	58.07%	57.58%	58.35%
Operating Margin	12.07%	11.84%	12.46%	14.83%	14.05%	14.12%
Pretax Margin	13.17%	13.62%	13.72%	15.33%	14.37%	14.00%
Profit Margin	9.37%	9.96%	10.05%	11.42%	11.05%	10.53%
FCF Margin	-	10.56%	9.02%	9.70%	9.41%	8.51%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 21, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	50.000	46.000	36.000	27.000	22.000	18.000
Dividend Per Share Growth	21.95%	27.78%	33.33%	22.73%	22.22%	28.57%
Dividend Yield	1.73%	1.91%	1.61%	0.91%	0.79%	0.97%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 21, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	20.73	15.89	16.30	21.88	23.96	20.05
Forward PE	17.65	16.34	15.19	20.08	24.15	19.94
P/FCF Ratio	18.14	14.99	18.16	25.77	28.15	24.82
PS Ratio	1.86	1.58	1.64	2.50	2.65	2.11

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error